The article examines the possibility of the drug lysergic acid diethylamide-25 (LSD) for use in the clinical treatment of illnesses such as cancer. Topics include an overview of a preliminary study in Switzerland by the head of the Swiss Medical Society for Psycholytic Therapy Peter Grasser, the challenges to studying psychedelics, and the experience of the patients who received them during the clinical trials.
© 2001-2025 Fundación Dialnet · Todos los derechos reservados